Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Audrey Wildeman

Physician Assistant Spartanburg, SC Physician Assistant

NPI 1437675469 CMS profile 11049720

3021 Reidville Rd, Spartanburg, SC 29301

Open in the dashboard

General payments

$4,785

312 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Audrey Wildeman of Spartanburg, SC is reported in the CMS Open Payments database as having received $4,785 across 312 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $68 4
2023 General $1,047 63
2022 General $1,681 112
2021 General $1,989 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Audrey Wildeman
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Audrey Wildeman were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Audrey Wildeman Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,989 $132 $37–$438 $132
2022 $1,681 $155 $48–$522 $149
2023 $1,047 $167 $52–$557 $160
2024 $68 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AstraZeneca Pharmaceuticals LP $628 22 payments
  2. AbbVie, Inc. $574 53 payments
  3. Esperion Therapeutics, Inc. $297 9 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $292 17 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $281 17 payments
  6. Amarin Pharma Inc. $279 20 payments
  7. Kowa Pharmaceuticals America, Inc. $268 26 payments
  8. Amgen Inc. $247 16 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $232 17 payments
  10. Sanofi-Aventis U.S. LLC $222 15 payments
  11. Other $1,464 100 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $4,785 312 payments
Products named General payments · program years 2021–2024
  1. BREZTRI $470 11 payments
  2. FARXIGA $458 9 payments
  3. NEXLETOL $297 9 payments
  4. XIFAXAN $281 17 payments
  5. Vascepa $279 20 payments
  6. VRAYLAR $265 24 payments
  7. TRINTELLIX $260 15 payments
  8. BEVESPI AEROSPHERE $246 3 payments
  9. Livalo $237 25 payments
  10. Kerendia $232 17 payments
  11. Other $3,761 254 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

312 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record